💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Cobimetinib

CHEMBL2146883 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
531.3 g/mol
LogP
3.9
Phase
4

A targeted cancer therapy that blocks a specific protein (MEK) involved in cell growth signaling pathways. It is often used in combination with other agents to treat certain types of cancer, including melanoma.

Молекулярная масса

531,3000 g/mol

LogP

3,90

TPSA

64,60 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Механизм действия

Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1

                

                

                
                

                    
InChI

                    
InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C21H21F3IN3O2

                    

                    
                    

                        
HBD / HBA

                        
3 / 7

                    

                    
                    

                        
Вращаемые Связи

                        
4

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
30

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
A targeted cancer therapy that blocks a specific protein (MEK) involved in cell growth signaling pathways. It is often used in combination with other agents to treat certain types of cancer, including melanoma.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Cobimetinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2146883.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 16222096.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.